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Abstract— Goal: Lithium preparations are considered the most 
reliable mood stabilizers for patients with Bipolar Disorder (BD), 
and are the most effective at reducing the risk of suicide. However, 
maintaining blood lithium concentration within the narrow 
therapeutic range of 0.4-1.2 mEq is crucial but extremely difficult. 
The aim of this work is to develop a personal lithium blood level 
analyzer using a novel method of combined optical and electrical 
impedance spectroscopy to test micro volumes of spiked samples 
of human blood.  
Results: Impedance measurements alone showed a limit of 
detection of less than 0.1 mEq within the therapeutic range, 
whereas optical measurements could verify the presence of lithium 
and provide a degree of lithium content. Optical specificity to 
lithium was further verified in qualitative assessment of lithium 
spiked blood samples with varying concentrations of sodium. 
Moreover, analysis of multiple linear regression yielded a 
prediction model of R2 = 0.322716 and RMSEP =0.223602 for 
optical measurements only using feature wavelengths, which were 
found to appear at minima 560 and 605 nm. Combined with 
impedance measurements, prediction of lithium concentration in 
samples with unknown lithium content was significantly increased 
to R2 = 0.876438, and RMSEP = 0.513554.  
Conclusion: The combination of optical and impedance modalities 
for determinations of blood lithium resulted in significant 
improvement to the sensitivity and accuracy of measurement. 
Significance: Results are complementary of the proposed opto-
impedance method, and future work will now focus on the 
technical development of an integrated and miniaturized system 
for measurement of lithium levels in blood with a high level of 
accuracy and sensitivity. 
Index Terms—Mental Health, Electrical Impedance, Bipolar 
Disorder, Spectrophotometry, Personal Monitoring.  
I. INTRODUCTION
IPOLAR Disorder (BD) is a lifelong and complex
psychiatric syndrome characterized by alternating episodes 
of mania and depression that can vary in duration and time of 
occurrence [1], [2]. People with BD experience recurrent and 
severe swings between elevated mood and depression. The 
result is serious impairment of functioning in personal, social 
and work life and the quality of life of a Bipolar person in 
general. BP is also associated with higher mortality through 
suicide [3] as well as poor physical health [4]. The importance 
of good illness control with safe prescribing, that is acceptable 
to patients, cannot be overestimated. Long term management of 
Bipolar patients involves regular taking of mood-stabilizing 
preparations such as lithium, which after 60 years, remains the 
most effective therapy for controlling acute mania, preventing 
relapses and reducing the risk of suicide [5]–[7].  
Long-term lithium treatment entails a considerable risk to the 
patient if not closely monitored, as the use of the drug must be 
controlled within a narrow therapeutic window of 0.6-1.0 mEq 
in serum (blood). Blood lithium levels above 1.5 mEq are 
considered toxic [8], and in many cases, lithium levels can 
increase above this limit, leading to serious consequences such 
as renal failure, seizures, coma and even death [9]. Toxicity can 
occur suddenly as a result of an overdose, drug interactions or 
dehydration [9].  
Bipolar patients on lithium medication are required to attend 
regular clinic visits to undergo frequent blood tests. In practice, 
the number of patients that conform with this requirement 
currently falls below set standards, and high rates of treatment 
non-adherence exists [10]. This is partly due to the frequency 
of blood tests resulting in patients evading treatment. Because 
of this, the availability of a personal monitor would benefit 
Bipolar patients by reducing the need for frequent clinical 
visits, empowering them through involvement in the 
management of their illness, as well as improving adherence 
with effective monitoring by facilitating early detection of 
shifting of lithium concentrations outside the therapeutic range. 
Methods for measuring lithium concentration in serum or 
plasma require high sensitivity to changes of <0.1 mM as 
toxicity levels are close to therapeutic levels. At present, the 
standard measurements of blood lithium concentration are 
performed via flame emission photometry (FEP) and atomic 
absorption spectroscopy (AAS) [11], [12]. Although both 
techniques provide the necessary accuracy and sensitivity of 
measurement, they are cumbersome and elaborate laboratory 
methods that cannot be translated into point of care devices for 
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personal monitoring. 
A handful of attempts to address the demand for personal 
monitoring of lithium have been reported, mainly through 
electrochemical methodologies such as Ion Selective Electrode 
(ISE) [13], [14] and electrophoresis [15], [16]. Some success 
has been achieved with these, but nevertheless, issues exist 
which relate to interference with other ions present in the 
sample [17], drifting of electrode-electrolyte interface 
impedance [18] and need for sample filtration [19]. 
Spectrophotometric [20] and spectrofluorimetric [21], [22] 
optical techniques have also been explored but these have 
focused on replacing current laboratory methods or used oral 
fluids as the testing media [23]. The latter have been linked to 
serum lithium levels, but are not standardized or clinically 
accepted as alternatives to serum levels.  
This work proposes the combination of optical and electrical 
impedance spectroscopy methods for measuring blood lithium 
concentrations. Optical spectroscopy techniques can offer a 
high degree of selectivity, whereas previous experimentation 
[24] has shown that electrical impedance spectroscopy can offer
a high degree of sensitivity to changes in ionic concentrations.
Hence, it is hypothesized that the combination of the two
methods would provide an enhanced degree of sensitivity and
specificity to changes in lithium concentration in blood.
II. MATERIALS AND METHODS
A. Preparation of blood samples
Following ethical approval, a standard solution of 60 mEq
Li2CO3 in deionized water was prepared, and subsequently, this 
was diluted further to make a set of solutions with the following 
concentrations: 12, 18, 24, 30, 36, 42, 48, 54 mEq.  
Frozen mixed pool blood plasma from healthy individuals 
was obtained from a reliable provider (TCS biosciences Ltd, 
Buckingham, UK). Samples of human plasma that have been 
spiked with lithium were prepared by mixing 1 mL from each 
reagent of Li2CO3 prepared earlier i.e. 18, 24, 30, 36, 42, 48, 54 
and 60 mEq with 29 mL of blood plasma, thus giving 8 samples 
of 30 mL, with lithium concentrations ranging between 0.4-
2.0 mEq. To check for repeatability of measurement, another 
set of samples were prepared in the same way using a different 
batch of blood plasma, as well as an additional set of samples 
spiked with unknown lithium concentrations in plasma. The 
latter were used to validate measurements. 
B. Reference flame photometry measurements
A flame photometer (M410 Sherwood Scientific Ltd,
Cambridge, UK) was used to measure the concentration of 
dissolved lithium in the plasma samples. Measurements of 
concentration are displayed in parts per million (ppm, 1mmol/L 
of Li+ is 6.93 ppm). Initially the instrument was left to warm up 
with the flame alight, and distilled water was aspirated for 
approximately 30 minutes. A standard solution provided by the 
manufacturer (containing 1.5 mM of Li+) was at first aspirated 
for 20 seconds and the instrument ppm reading was set to 10.4 
(corresponding to 1.5 mM). Successive measurements of 
known and unknown lithium concentrations from the prepared 
plasma samples were recorded, then used to extrapolate molar 
lithium concentration. 
C. Optical measurements of blood lithium
The following reagents were prepared: 0.1 M of NaOH, 0.25
M of Na2CO3, 90 % (CH3)2SO and 1 mM of Quinizarin in 
(CH3)2SO.  
An amount of 500 µL from spiked samples of plasma were 
pipetted into a test tube, then were diluted with water to make 
up to 1 mL. An amount of 50 µL from diluted plasma was 
mixed with 100 µL of 0.1 M NaOH, 10 µL of 0.25 M Na2CO3, 
40 µL of water, 2.15 mL of 90 % (CH3)2SO and 50 µL of 1mM 
of Quinizarin in (CH3)2SO. Prior to testing, all samples were 
kept in a thermostatic bath at 25º for 30 mins.  
Data was acquired using a dual beam spectrophotometer 
(Model: Lambda 1050, PerkinElmer Corp, Waltham, MA) with 
the Traycell (Helma GmbH & Co, Mulheim, Germany), which 
only requires 4-5 µL of sample volume for analysis.  
The instrument was setup to acquire spectra between 450-
700 nm at increments of 1 nm, with a response time of 0.2 secs 
and two running cycles for each sample. Slit width of the 
detector was fixed at 2 nm, and both reference and sample 
attenuators were kept at 100 %. Data pre-treatment, Partial 
Least Squares (PLS) and Multiple Linear Regression (MLR) 
analysis were performed using the Matlab® software 
(Mathworks Inc, Novi, MI), and the PLS-toolbox (Eigenvector 
Research Inc, Manson, WA) Matlab® add-on. Pre-processing 
methods which were applied to acquired spectra include 
baseline correction using the Whittaker filter, and Savitsky-
Golay algorithms for both smoothing and second derivatives.  
Since sodium fluctuations are the most likely to influence 
measurement, additional tests were performed to study the 
influence of sodium ion variation in blood. For this, four blood 
samples that had been spiked with lithium at 0.6, 1.0, 1.2 and 
1.8 mmol/L of Li+ were selected and from each of these, four 
additional samples were prepared by mixing 0.33 mL of 
deionized water, or 30, 45, or 60 mEq Na2CO3 with 9.78 mL of 
lithium spiked blood plasma. This provided a set of 16 samples 
with increased sodium concentration of 0, 1, 1.5 and 2.0 
mmol/L. 
D. Tetrapolar electrical impedance measurements of blood
lithium
Tetrapolar electrical impedance measurements typically 
involve the injection of a low amplitude ac current into the 
sample under test (SUT) through a pair of current carrying (CC) 
electrodes and a separate pick up (PU) electrode pair used to 
monitor the resulting voltage. The relationship between the 
injected current and the measured voltage allows for the 
calculation of impedance. Since lithium is present in blood in 
its ionic form, the tetrapolar (4-electrode) probe contacting the 
sample will detect changes to Li concentration as changes to the 
electrical conductivity/impedivity of blood. Therefore, 
variations in the recorded voltage can directly translate to blood 
lithium concentration changes. A more detailed explanation of 
the method can be found in [24], where the sensitivity of the 
method to changes in lithium concentration in human blood 
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plasma was tested and benchmarked. The probe presented in 
this paper consists of a co-planar 4-electrode arrangement 
shown in Fig 1. It was designed methodically using COMSOL 
FEM simulations prior to its fabrication to determine its 
sensitivity to changes in the conductivity of the SUT. Its 
electrode array geometry was thus optimized for enhanced 
resolution in small sample volumes (160μL). This design 
exhibited a significant improvement relative to a previous, 
larger (3mL) probe designed and tested by the authors and 
presented in [24].  
Fig 1.  (a) The fabricated 160μL tetrapolar impedance probe (b) COMSOL 
model and geometrical configuration of the probe. Partitioned mesh was 
produced by assigning finer mesh geometry to the “SUT” domain. 
The new probe features a tenfold increase in the total 
sensitivity, corresponding to a tenfold increase in the measured 
impedance change for specific Li concentration variations. 
Hence, with appropriately designed instrumentation for 
tetrapolar impedance measurements, the new probe has the 
potential to measure very small Li concentration variations.   
Electrical impedance measurements using human plasma 
solutions spiked with lithium carbonate (Li2CO3) at different 
concentrations were performed using the Agilent 4294A 
precision impedance analyzer in a frequency bandwidth from 
30 kHz to 300 kHz. Each measurement acquired 201 points 
throughout the bandwidth for both magnitude and phase of the 
sample’s impedance and average respective values were 
calculated from these points. The measurements were repeated 
5 times for each sample for statistical analysis. An initial 
baseline reference measurement using a plasma only solution 
was taken, and results are reported as the mean change in 
impedance magnitude and phase relative to that reference value. 
E. Combination of optical and electrical impedance
spectroscopy measurements
Overall, analysis of each prepared sample was carried out 
using both optical and impedance modalities (on two separate 
platforms), and data collected was used to assess each modality 
separately, and in combination, by using regression techniques 
to test the accuracy and sensitivity of lithium calibration and 
prediction in blood.  Fig 2 provides a diagrammatic illustration 
of the measurement process.  
III. RESULTS AND DISCUSSIONS
Samples of blood plasma, which were prepared to give 
lithium contents of 0.4-2.0 mEq in the order of 0.2 mEq, were 
first verified through FEP measurements, and are listed here in 
Table I. Linear regression was performed on FEP readings 
against set concentrations, where a positive correlation of R2 = 
0.882 was found between both sets (Fig 3). FEP values were 
also used to extrapolate molar values of lithium in prepared 
blood samples, the result of which is summarized in Table I. It 
is assumed that the differences between set and measured Li+ 
levels exist because samples were comprised of two sets 
prepared from different batches of blood which differ in 
homogeneity and lithium baseline. A paired t-test showed that 
extrapolated Li+ concentrations were statistically significantly 
different from set values (p = 0.0016). Since FEP measurements 
are considered the standard in measuring lithium, the remainder 
of analysis was performed using values extrapolated from flame 
photometer readings.  
A. Optical Spec. results
Preprocessed spectral data of spiked samples of blood plasma
are shown in Fig 4. These feature prominent minima bands 
around 605 nm and 560 nm. Once again, results include data 
Fig 2. Process diagram of combined optical and electrical impedance method used to analyze lithium spiked samples of human blood. 
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from two sets of lithium spiked samples of blood (plasma) 
prepared from different batches. Thus, baseline correction was 
performed on raw data from the two sets separately prior to 
performing additional preprocessing treatments of Savitsky-
Golay second derivative and smoothing, peak shift correction 
(using minima at 605 nm as a reference point) and area 
normalization (range selected: 530-650nm). A general trend is 
evident where minima values, and in turn absorbance, around 
the bands of 605 and 560 nm varied in correspondence with 
lithium concentrations, thereby increasing with higher blood 
lithium contents. However, results also indicate a lack of 
sensitivity, particularly when measurements from different 
blood batches are considered.  
TABLE I 
FEP MEASUREMENTS OF LITHIUM CONCENTRATIONS IN 
HUMAN BLOOD (PLASMA) 
Fig 3. Calibration curve of FEP measurements of Li+ concentration in spiked
samples of human blood (plasma). 
This is particularly evident when assessing the relationship 
between acquired spectra and lithium levels in plasma samples 
through Multiple Linear Regression (MLR), using full range 
data of pre-treated spectra between 530-650 nm. Spectral data 
were used as calibration data input whilst lithium 
concentrations obtained through FEP measurements were used 
as the dependent variable. Prior to producing the model, mean-
centering and leave-one-out cross validation was applied, 
which ensured that the performance of the model is optimized. 
The results of regression (inset of Fig 4) yielded an R2 value of 
1 but a significantly lower cross-validated R2 value of 0.5514. 
Fig 4. Second derivative spectra of therapeutic concentrations of lithium in 
blood in the range 530-650 nm after undergoing pre-treatment of baseline and 
peak shift corrections, Savistky-Golay filtering and normalization. Prominent 
bands found at 605 nm and 560 (circled). 
This reduction is assumed to relate to differences in baseline 
and homogeneity between the two sets of blood samples, which 
although minimized through pre-processing, remain to decrease 
the accuracy of measurement. Similarly, the Root Mean Square 
Error (RMSE) of calibration (RMSEC: 2.32898e-15) was also 
found to be higher in cross-validation RMSE (RMSECV = 
0.296932).   
In addition to quantitative determinations of blood lithium 
levels, the degree of specificity to lithium using the proposed 
method was also investigated. Spectral measurements were 
collected from lithium spiked blood samples that had been 
mixed with Na2CO3, and underwent processing of baseline 
correction, Savitsky-Golay smoothing and area normalization. 
The resulting graphs are illustrated in Fig 5, showing four sets 
of measurements from four selected lithium spiked blood 
samples whose sodium contents were varied by specified 
amounts. An averaged spectrum of the respective lithium 
spiked blood (plasma) was used as a blank and subtracted from 
the graphs shown in Fig 5.  
Looking at Fig 5, it is evident that a peak shift existed 
between the band relating to lithium absorption and that 
belonging to the sodium ion. Although actual bands are seen to 
vary between measurements, being located around 605-625nm 
for lithium and between 580-600nm for sodium, each set of 
spectral data clearly exhibited a difference of ≈20nm between 
the absorption bands of the two ions of interest, thereby 
indicating the possibility of high selectivity to lithium in blood 
with this method. 
Li+ (mM) = FEP (ppm)/6.6941 
Baseline of FEP (ppm) = 10.4/6.6941 = 1.4983 Li+(mmol/L) 
Conc (mEq) FEP (ppm) Li+ (mM) 
2.00 12.90 1.86 
1.80 10.70 1.54 
1.40 8.40 1.21 
1.60 8.60 1.24 
1.20 6.70 .97 
1.00 6.40 .92 
.80 6.80 .98 
.60 5.20 .75 
.40 3.60 .52 
.00 .50 .07 
.00 .60 .09 
.60 3.40 .49 
.80 4.20 .61 
1.00 4.55 .66 
1.20 5.50 .79 
1.40 6.90 .99 
1.60 7.60 1.10 
1.80 8.70 1.25 
2.00 9.50 1.37 
2.00 12.90 1.86 
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As mentioned earlier, spectrophotometric measurements 
showed two minima bands around 560 and 605 nm that related 
to the presence of lithium in blood samples. To eliminate the 
need for broad range spectral data for diffuse visible 
spectroscopy, which can complicate the implementation of this 
method into a simple and personal monitoring device, optical 
wavelengths which expressed the highest regression 
coefficients were selected and used as input into dual 
wavelength optical analysis. These were obtained by extracting 
minima values around the selected regions from full range 
spectra. Linear regression analysis was then performed to test 
the possibility of calibration and prediction accuracy of lithium 
in blood using dual wavelength measurement. Validations were 
carried out by testing samples with unknown blood lithium 
concentrations. The descriptive statistics summarized in Table 
III provide an overview of the mean and standard deviation of 
the samples used in this analysis.  
Table IV summarizes the prediction statistics and the 
performance of the regression analysis with selected feature 
wavelengths. Low performance for both calibration (R2 = 
0.2972) and prediction of lithium (R2 = 0.322716) was 
observed using the dual wavelength method, as well as higher 
estimation of calibration error (RMSEC = 0.3036). The 
measured versus predicted blood lithium levels and error of 
estimation resulting from the regression are illustrated in Fig 6. 
For further comparison of the optical method in relation to 
Fig 5. Preprocessed absorption spectra of a set of lithium spiked blood solutions (0.6, 1.0, 1.2, and 1.8 mmol/L Li+ whose sodium concentrations were altered 
by 0, 1.0, 1.5, and 2.0 mmol/L Na+ for qualitative assessment of the effects of changes in sodium concentrations in spiked lithium samples. 
Fig 6. Measured versus predicted concentration of lithium ion in blood 
(plasma) using dual wavelength optical measurements only.  
Fig 7. Bland Altman plot showing the difference against the average of dual 
wavelength method and standard FEP measurements of blood lithium 
concentration. Broken line (----) indicates the limits of agreement 
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reference FEP measurements, agreement analysis was 
performed using the Bland Altman method. The resulting plot 
is shown here in Fig 7. General agreement is evident between 
optical and reference FEP measurements. Though a single 
variable is present outside the confidence limit and the 
magnitude of variation i.e. the confidence limits, are evidently 
large (-0.6 to 0.6 mmol/L) in relation to the required sensitivity 
for discriminating blood lithium levels within the therapeutic 
range.   
B. Impedance Spec. results
Electrical impedance measurements of blood plasma only
and blood plasma with dissolved Li2CO3 are shown in Table II 
and Fig. 8. A reduction in the mean impedance magnitude is 
observed from the plasma only solution with increasing Li2CO3 
concentration (Table II). The calculated t-values reflect the 
difference in mean impedance magnitude between samples with 
the null hypothesis that there is no significant difference 
between them. Fig. 8(top) shows a plot of the change in the 
mean impedance magnitude (absolute change) with increasing 
Li+ concentration.  There is no significant change in the 
observed impedance phase as shown in Fig. 8(bottom). This, 
however, is expected as blood plasma contains only protein 
molecules, water and ions and thus can be considered as a 
conductive solution with the absence of any reactive species. 
Cell membranes can be considered as reactive species as they 
behave like tiny imperfect capacitors due to their bilayer 
structure and blood plasma is free of any cell-like structures.  
TABLE II 
ELECTRICAL IMPEDANCE MEASUREMENTS OF BLOOD PLASMA 
ONLY AND BLOOD PLASMA WITH DISSOLVED Li2CO3. MEAN 
VALUES FOR A BANDWIDTH BETWEEN 30 KHZ AND 300 KHZ. 
Concentration (mM)* |Z| ± SE (Ω)** |t |*** φ(Z) ± SE (deg.) ** 
Plasma only 3225.33 ± 1.66 ------- -5.44 ± 0.01 
0.49 3210.87 ± 0.89 17.10 -5.49 ± 0.01 
0.61 3200.72 ± 2.39 8.88 -5.52 ± 0.01 
0.66 3178.52 ± 1.13 18.74 -5.48 ± 0.01 
0.79 3167.04 ± 3.04 7.91 -5.47 ± 0.01 
0.99 3154.34 ± 3.62 6.01 -5.44 ± 0.01 
1.10 3148.58 ± 2.25 3.02 -5.43 ± 0.01 
1.37 3145.40 ± 0.77 2.98 -5.43 ± 0.01 
1.86 3140.41 ± 1.47 6.69 -5.42 ± 0.01 
* Li+ concentration ** Mean *** t[0.05]=1.86 (df=N1+N2-2), N1=N2=5 
Hence changes to the concentration of dissolved species
would be reflected to changes in the impedance magnitude (due 
to change in the ionic content) and not to the phase (due to 
absence of any reactive species). Measured results indicate the 
suitability of the method to detect changes in the concentration 
of Lithium in blood plasma to <0.1mM. Error bars show the 
standard error in the reading taken from five individual 
measurements of the same solution. 
C. Opto-impedance Spec. results
As mentioned earlier, electrical impedance measurements of
spiked blood samples were capable of rapid and very accurate 
i.e. in the order of 0.1 mEq, determinations of conductivity in
relation to changes in concentration of lithium ions. For the 
same sets of samples, spectrophotometric measurements 
showed two minima bands around 560 and 605 nm which 
related to the presence of lithium in blood samples, but with a 
lower degree of accuracy for predicting lithium concentration 
(around 55%), and even lower when considering selected 
feature wavelengths alone. Thus, optical measurements provide 
sufficient specificity for detecting lithium, whilst the method of 
electrical impedance offers exceptional accuracy in 
conductivity variations, but lacks specificity to a single 
element. For this reason, it is believed that the integration of 
optical and impedance measurement can provide an improved 
method for lithium determinations in blood.  
TABLE III 
DESCRIPTIVE STATISTICS OF REFERENCE FEP READ AND 
PROCESSED DATA OF EI AND FEATURE WAVELENGTHS OF 
OPTICAL MEASUREMENTS 
No of 
sample
s 
Min Max Mean 
Std. 
Deviatio
n 
FEP 15 0.3458 1.7289 0.8798 0.3749 
Wavelength_1 15 -0.0070 0.0730 0.0290 0.0238 
Wavelength_2 15 -0.0144 0.1439 0.0467 0.0404 
Impedance 15 
14.455
5 
96.606
3 
52.117
1 
27.3521 
Fig 8. Results of changes in impedance (top) and phase (bottom) in relation 
to blood lithium concentrations. 
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Using the data acquired from the optical wavelengths which 
expressed the highest regression coefficients, together with 
measurements of electrical impedance, linear regression 
analysis was performed to test the possibility of calibration and 
prediction accuracy of lithium in blood using opto-impedance 
measurement. The descriptive statistics summarized in Table 
III provide an overview of the mean and standard deviation of 
the samples used in the analysis i.e. the two feature wavelengths 
from optical measurements and impedance data. 
Similar to the previous analysis, mean centering and cross-
validation through the leave-one-out were performed on the 
data prior to regression. Input data were also normalized to a 
length of 1 to account for differences between optical and 
impedance measurement. The precision and accuracy of the 
regression analysis was evaluated by using a set of samples with 
unknown lithium content as input for validation. These were 
prepared as described in Section 2(a).  
Table IV summarizes the prediction statistics and the 
performance of the regression analysis with combined optical 
and impedance measurements. In this case, the addition of 
impedance measurements had a significant influence on 
improving the calibration and prediction of lithium levels in the 
blood samples. Compared to optical measurements alone, opto-
impedance analysis had good performance for both calibration 
(R2 = 0.9122) and cross-validation (R2 = 0.824603), and the 
concentration of lithium in blood samples can be predicted with 
an accuracy of R2 = 0.8764, although its prediction error 
(RMSEP = .5136) was higher compared to that of the dual 
wavelength method (RMSEP = 0.2236). The measured versus 
predicted blood lithium levels and error of estimation resulting 
from regression of opto-impedance measurements are 
illustrated in Fig 9. 
In addition, Bland Altman analysis of agreement between 
opto-impedance and standard FEP measurements showed 
closer agreement between the two methods (Fig 10) in 
comparison to optical measurements alone, shown earlier in Fig 
7. A reduction in the magnitude of variation is also evident, this
time ranging between -0.2-0.2 mmol/L, which is sufficient to
discriminate lithium levels within its therapeutic range, and
similar to Fig 7, a single outlier is observed, though the
magnitude of variation is less.
Fig 10. Bland Altman plot showing the difference against the average of opto-
impedance and standard FEP measurements of blood lithium concentration. 
Broken line (----) indicates the limits of agreement. 
IV. CONCLUSIONS
A combined method of spectrophotometric and electrical 
impedance measurement on blood plasma containing lithium 
levels in the therapeutic range normally found in Bipolar 
patients being treated with lithium medication was investigated. 
Using each method separately, it was found that electrical 
impedance is capable of highly accurate conductivity 
measurement, which can detect changes in lithium 
TABLE IV 
COMPARISON OF PREDICTION ABILITY OF BLOOD LITHIUM LEVELS WITH MLR ANALYSIS USING FEATURE OPTICAL 
WAVELENGTHS, AND COMBINED OPTO-IMPEDANCE MEASUREMENTS. 
Calibration Cross-validation Prediction 
Dual λ Opto-Impedance Dual λ Opto-Impedance Dual λ Opto-
Impedance 
RMSE  0.303625  0.107321 0.334277 0.151728 0.223602 0.513554 
Bias 0 1.11022e-16 -0.0118774 -0.00338763 0.119889 0.425177 
R2 0.297209 0.912195 0.17172 0.824603 0.322716 0.876438 
Fig 9. Measured versus predicted concentration of lithium ion in blood 
(plasma) using improved opto-impedance method. 
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concentration in the order 0.1mmol/L, whereas optical 
measurements were able to verify the presence of lithium in 
blood samples and provide some degree of lithium content. 
Specificity to lithium was further verified in qualitative 
assessment of lithium spiked blood samples with varying 
concentrations of sodium.  
Results of multiple linear regression performed once using 
only feature wavelengths of optical measurements and again 
using the proposed combination method, showed significant 
improvement in both calibration and prediction with opto-
impedance measurement, as well as reduced error of calibration 
and cross validation. Using blood (plasma) samples with 
unknown lithium content, the opto-impedance method provided 
considerably better prediction of lithium content and reduced 
error of measurement between samples. 
 In conclusion, combined optical and electrical impedance 
analysis can be most complementary particularly in this case, 
providing the benefit of both specificity and accuracy to lithium 
blood content. Future work will focus on further technical 
development of an integrated and miniaturized system suitable 
for personal monitoring of blood lithium levels in Bipolar 
patients.   
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